An Exploratory Analysis of the Cost-Effectiveness of a Multi-cancer Early Detection Blood Test Compared with Standard of Care Screening in Ontario, Canada
ConclusionThe main contribution of the study is to present and execute a methodological approach that can be adopted to test the cost effectiveness of an MCED tool in the Canadian setting. The model is also sufficiently generic that it could be adapted to other jurisdictions, and with consideration for increasing the WTP threshold beyond the common $100,000 per QALY limit, given the life-threatening nature of cancer, to ensure that MCED interventions are cost-effective. (Source: PharmacoEconomics)
Source: PharmacoEconomics - December 27, 2023 Category: Health Management Source Type: research
A Research Framework to Improve Health Disparity Evidence Gaps in Value Assessments
AbstractA value assessment is intended as a tool for evaluating healthcare treatments to gauge value and inform decisions. Economic value assessments typically incorporate a cost-effectiveness analysis, focusing on costs and health outcomes important to payers, missing important information to ensure existing markets optimize resource allocation. Despite frequent calls for more explicit consideration of health equity impacts in value assessments, health economists continue to develop models informed by traditional cost and quality-of-life data that do not capture differences experienced by health disparity populations. Thi...
Source: PharmacoEconomics - December 12, 2023 Category: Health Management Source Type: research
A Framework for the Fair Pricing of Medicines
AbstractAs high-cost medicines put increasing pressure on public health care budgets, the need to identify ‘fair’ prices for medicines has never been greater. This paper proposes a framework, built upon fundamental economic principles, that allows for the consideration of ‘fair’ prices for medicines. The framework incorporates key considerations from conventional supply-side and demand-side appro aches for specifying a cost-effectiveness ‘threshold’, including the health opportunity cost borne by other patients (\(k\)) and society ’s willingness to pay for marginal improvements in population health (\(v\)). T...
Source: PharmacoEconomics - December 8, 2023 Category: Health Management Source Type: research
Recommendations for Emerging Good Practice and Future Research in Relation to Family and Caregiver Health Spillovers in Health Economic Evaluations: A Report of the SHEER Task Force
ConclusionsConsideration of health spillovers in economic evaluations has been called for by researchers and policymakers alike. Accordingly, it is hoped that the consensus recommendations of SHEER will motivate more widespread incorporation of health spillovers into analyses. The developing nature of spillover research necessitates that this guidance be viewed as an initial roadmap, rather than a strict checklist. Moreover, there is a need for balance between consistency in approach, where valuable in a decision making context, and variation in application, to reflect differing decision maker perspectives and to suppor...
Source: PharmacoEconomics - December 2, 2023 Category: Health Management Source Type: research
Estimating the Treatment and Prophylactic Economic Value of New Antimicrobials in Managing Antibiotic Resistance and Serious Infections for Common Pathogens in the USA: A Population Modelling Study
ConclusionsThe use of a new antimicrobial for treatment and prophylactic indications yields considerable clinical and economic benefits including transmission diversity and enablement value. These findings may provide decision makers with important evidence to support investment in new antimicrobials and antimicrobial stewardship policy that address the patient, population and system burden associated with antimicrobial resistance. (Source: PharmacoEconomics)
Source: PharmacoEconomics - November 24, 2023 Category: Health Management Source Type: research
Surrogacy and the Valuation of ATMPs: Taking Our Place in the Evidence Generation/Assessment Continuum
AbstractMedical technology is advancing rapidly, but established methods for health technology assessment are struggling to keep up. This challenge is particularly stark for the assessment of advanced therapy medicinal products —therapies often launched on the basis of single-arm studies powered to a surrogate primary endpoint. The most robust surrogacy methods investigatetrial-level correlations between the treatment effect on the surrogate and the outcome of ultimate interest. However, these methods are often impossible with the evidence usually available for advanced therapy medicinal products at the time of the launc...
Source: PharmacoEconomics - November 22, 2023 Category: Health Management Source Type: research
Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid
ConclusionsReal-world data indicates substantial uncertainty and extended payback periods for gene therapy costs. Utilizing real-world data, Medicaid can negotiate value-based contracts to manage budget fluctuations, share risk with manufacturers, and enhance patient access to innovative treatments. (Source: PharmacoEconomics)
Source: PharmacoEconomics - November 21, 2023 Category: Health Management Source Type: research
Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Group Perspective
(Source: PharmacoEconomics)
Source: PharmacoEconomics - November 20, 2023 Category: Health Management Source Type: research
